Erudio Healtherudio.com
Sponsor
Shanghai JMT-Bio trials: what clinicians said in public
HCP commentary reports on 2 clinical trials sponsored by Shanghai JMT-Bio: KC-WISE and Neo-Healer. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Shanghai JMT-Bio Inc.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Neo-Healer NCT06747338 · Shanghai JMT-Bio Inc. | early or locally advanced HER2-positive breast cancer | Phase 3 | 104 | 21 | Focused | Nov 20, 2026 | Preview |
| KC-WISE NCT05427383 · Shanghai JMT-Bio Inc. | HER2-positive advanced gastric cancer after failed first-line therapy | Phase 2/Phase 3 | 77 | 25 | Focused | Nov 19, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| NCT05132777 NCT05132777 · Shanghai JMT-Bio Inc. FocusedView → | Not given | Phase 2 | Focused | View | |||
| HEALER NCT05838066 · Shanghai JMT-Bio Inc. FocusedView → | first-line HER2-positive recurrent or metastatic breast cancer | Phase 3 | Focused | View | |||